Home LiteratureArticle Details
PMID: 17105688 Published · ppublish English Journal Article Review

The role of antibiotic and probiotic therapies in current and future management of inflammatory bowel disease.

Current gastroenterology reports ·Vol. 8 ·No. 6 ·2006-12-00 ·Pages 486-98

Ewaschuk JB, Tejpar QZ, Soo I, Madsen K, Fedorak RN

Abstract

Abundant evidence indicates that the intestinal microflora have a role in the pathogenesis of inflammatory bowel disease (IBD). The composition of the gut microflora is altered in IBD patients with increased "pathogenic" bacteria and decreased bifidobacteria and lactobacilli. In light of this dysbiosis, various methods have been examined to alter the composition of the intestinal microflora, including the administration of antibiotics and introduction of probiotic species. This article summarizes studies evaluating the efficacy of antibiotics and probiotics in the induction and maintenance of remission of ulcerative colitis, Crohn's disease, and pouchitis.

MeSH Terms
Anti-Bacterial Agents/therapeutic use Humans Inflammatory Bowel Diseases/drug therapy Probiotics/therapeutic use Remission Induction/methods Treatment Outcome
Chemicals
Anti-Bacterial Agents
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Ewaschuk Julia B
Division of Gastroenterology, Zeidler Family Gastrointestinal Health and Research Centre, Zeidler Ledcor Building, 130 University Campus, Edmonton, AB, Canada T6G 2C8.
Tejpar Qassim Z
Soo Isaac
Madsen Karen
Fedorak Richard N
References (53)
53 references, click to expand
  1. Mucosal flora in inflammatory bowel disease.
    Gastroenterology. 2002 Jan;122(1):44-54 PMID: 11781279
  2. Probiotics and the management of inflammatory bowel disease.
    Inflamm Bowel Dis. 2004 May;10(3):286-99 PMID: 15290926
  3. Treatment of ulcerative colitis using fecal bacteriotherapy.
    J Clin Gastroenterol. 2003 Jul;37(1):42-7 PMID: 12811208
  4. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial.
    Gastroenterology. 2003 May;124(5):1202-9 PMID: 12730861
  5. Open label trial of oral clarithromycin in active Crohn's disease.
    Aliment Pharmacol Ther. 2000 Jun;14(6):801-6 PMID: 10848665
  6. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD)
    Clin Exp Immunol. 1995 Dec;102(3):448-55 PMID: 8536356
  7. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora.
    Aliment Pharmacol Ther. 2003 Feb 15;17(4):509-15 PMID: 12622759
  8. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial.
    Gastroenterology. 2000 Aug;119(2):305-9 PMID: 10930365
  9. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis.
    J Am Coll Nutr. 2003 Feb;22(1):56-63 PMID: 12569115
  10. Probiotic bacteria enhance murine and human intestinal epithelial barrier function.
    Gastroenterology. 2001 Sep;121(3):580-91 PMID: 11522742
  11. A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis.
    Scand J Gastroenterol. 2001 Sep;36(9):971-4 PMID: 11521989
  12. Is lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary, open-label study.
    J Pediatr Gastroenterol Nutr. 2000 Oct;31(4):453-7 PMID: 11045848
  13. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.
    BMJ. 1989 Jan 14;298(6666):82-6 PMID: 2563951
  14. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease?
    J Clin Gastroenterol. 1997 Dec;25(4):653-8 PMID: 9451682
  15. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine.
    Gut. 2004 Nov;53(11):1617-23 PMID: 15479682
  16. Rifaximin-ciprofloxacin combination therapy is effective in chronic active refractory pouchitis.
    Colorectal Dis. 2005 Mar;7(2):182-6 PMID: 15720360
  17. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis.
    Gut. 1986 Oct;27(10):1210-2 PMID: 3536677
  18. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial.
    Gastroenterology. 2005 Apr;128(4):856-61 PMID: 15825069
  19. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial.
    Gastroenterology. 2002 Jul;123(1):33-40 PMID: 12105831
  20. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis.
    Inflamm Bowel Dis. 2001 Nov;7(4):301-5 PMID: 11720319
  21. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease.
    Inflamm Bowel Dis. 2005 Sep;11(9):833-9 PMID: 16116318
  22. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin.
    Am J Gastroenterol. 1996 Feb;91(2):328-32 PMID: 8607501
  23. Double blind, placebo controlled trial of metronidazole in Crohn's disease.
    Gut. 1991 Sep;32(9):1071-5 PMID: 1916494
  24. Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells.
    J Biol Chem. 2002 Dec 27;277(52):50959-65 PMID: 12393915
  25. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).
    Am J Gastroenterol. 1999 Mar;94(3):674-8 PMID: 10086650
  26. Rifaximin for active ulcerative colitis.
    Inflamm Bowel Dis. 2006 Apr;12(4):335 PMID: 16633057
  27. Saccharomyces boulardii in maintenance treatment of Crohn's disease.
    Dig Dis Sci. 2000 Jul;45(7):1462-4 PMID: 10961730
  28. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin.
    Aliment Pharmacol Ther. 2006 Apr 15;23(8):1117-25 PMID: 16611272
  29. Oral tobramycin in ulcerative colitis: effect on maintenance of remission.
    Aliment Pharmacol Ther. 1993 Apr;7(2):155-8 PMID: 8485268
  30. Assessment of mucosal inflammation and blood flow in response to four weeks' intervention with probiotics in patients operated with a J-configurated ileal-pouch-anal-anastomosis (IPAA).
    Scand J Gastroenterol. 2004 Dec;39(12):1228-35 PMID: 15743000
  31. Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls.
    Scand J Gastroenterol. 2002 Sep;37(9):1034-41 PMID: 12374228
  32. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.
    Lancet. 1999 Aug 21;354(9179):635-9 PMID: 10466665
  33. Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis.
    Aliment Pharmacol Ther. 2002 May;16(5):909-17 PMID: 11966499
  34. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis.
    Aliment Pharmacol Ther. 1999 Aug;13(8):1103-8 PMID: 10468688
  35. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis.
    Aliment Pharmacol Ther. 2004 Nov 15;20(10):1133-41 PMID: 15569116
  36. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis.
    Aliment Pharmacol Ther. 2006 Jun 1;23(11):1567-74 PMID: 16696804
  37. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial.
    Gut. 2006 Jun;55(6):842-7 PMID: 16377775
  38. Probiotics in man and animals.
    J Appl Bacteriol. 1989 May;66(5):365-78 PMID: 2666378
  39. Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study.
    Gastroenterology. 1998 Nov;115(5):1072-8 PMID: 9797360
  40. Lactobacillus acidophilus (strain LB) from the resident adult human gastrointestinal microflora exerts activity against brush border damage promoted by a diarrhoeagenic Escherichia coli in human enterocyte-like cells.
    Gut. 2002 Jun;50(6):803-11 PMID: 12010882
  41. Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis.
    Am J Gastroenterol. 1994 Jan;89(1):43-6 PMID: 8273796
  42. Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro.
    Gut. 2003 Jun;52(6):827-33 PMID: 12740338
  43. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection.
    Gastroenterology. 1995 Jun;108(6):1617-21 PMID: 7768364
  44. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG.
    Gut. 2002 Sep;51(3):405-9 PMID: 12171964
  45. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats.
    J Clin Invest. 1996 Aug 15;98(4):945-53 PMID: 8770866
  46. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis.
    Am J Gastroenterol. 2005 Jul;100(7):1539-46 PMID: 15984978
  47. A pilot trial of Saccharomyces boulardii in ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2003 Jun;15(6):697-8 PMID: 12840682
  48. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis.
    Gut. 2004 Jan;53(1):108-14 PMID: 14684584
  49. Lactobacillus GG in inducing and maintaining remission of Crohn's disease.
    BMC Gastroenterol. 2004 Mar 15;4:5 PMID: 15113451
  50. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice.
    Infect Immun. 1998 Nov;66(11):5224-31 PMID: 9784526
  51. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result.
    Gastroenterology. 1982 Sep;83(3):550-62 PMID: 6124474
  52. Towards understanding molecular modes of probiotic action.
    Curr Opin Biotechnol. 2006 Apr;17(2):204-10 PMID: 16510275
  53. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC).
    Gut. 2003 Jul;52(7):988-97 PMID: 12801956
Article Info
Journal
Current gastroenterology reports
Abbr.
Curr Gastroenterol Rep
ISSN
1522-8037
DOI
10.1007/s11894-006-0039-z
Published
2006-12-00
Pages
486-98
Language
English
Region
United States
NLM ID
100888896
Subset
IM
Grants
Canadian Institutes of Health Research · 49434-2 · Canada
External Links
PubMed source DOI: 10.1007/s11894-006-0039-z View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2